01731nas a2200229   4500000000100000000000100001008004100002260000900043653002100052653001600073653001300089653001900102653001400121653002300135653003200158100001900190245010200209300001100311490000600322520115900328022001401487       2021                            d  c202110aAMED-MPS project10acholestasis10afibrosis10aliver zonation10aliver-MPS10along-term exposure10amicrophyisiological systems1 aSeiichi Ishida00aResearch and Development of Microphysiological Systems in Japan Supported by the AMED-MPS Project  a6577650 v33 aMicrophysiological systems (MPS) have been actively developed as a new technology for in vitro toxicity testing platforms in recent years. MPS are culture techniques for the reconstruction of the specific functions of human organs or tissues in a limited space to create miniaturized human test systems. MPS have great promise as next-generation in vitro toxicity assessment systems. Here, I will review the current status of MPS and discuss the requirements that must be met in order for MPS to be implemented in the field of drug discovery, presenting the example of an in vitro cell assay system for drug-induced liver injury, which is the research subject in our laboratory. Projects aimed at the development of MPS were implemented early in Europe and the United States, and the AMED-MPS project was launched in Japan in 2017. The AMED-MPS project involves industry, government, and academia. Researchers in the field of drug discovery in the pharmaceutical industry also participate in the project. Based on the discussions made in the project, I will introduce the requirements that need to be met by liver-MPS as in vitro toxicity test platforms.  a2673-3080